Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity

The diabetes drug semaglutide, also known as Ozempic, has a positive effect for patients with chronic kidney damage and obesity. They

Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with placebo, despite similar levels of continuing symptoms in the two groups

June 27, 2024

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab – Biotech Investments

EQS-News: Lindis Biotech GmbH / Key word(s): Agreement LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab 19.11.2024 / 10:07 CET/CEST The

November 20, 2024

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

Combining the anti-CD38 monoclonal antibody isatuximab (Sarclisa) with the standard backbone of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) significantly improved progression-free survival (PFS) in

June 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.